Eli Lilly stock down on Q4 guidance miss
Lilly revised its revenue guidance down 5%, to $13.5 billion, missing consensus of $14 billion by $500 million. But the guidance still represents a 45% increase from the same quarter in 2023. Lilly previously provided a range of $13.9 billion to $14.5 billion. The company also provided full-year 2024 guidance of $45 billion, or 32% more than 2023.
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
--Up 15.51% from 52 weeks ago (Jan. 16, 2024), when it closed at $634.57 --Down 23.65% from its 52-week closing high of $960.02 on Aug. 30, 2024 --Up 17.59% from its 52-week closing low of $623.35 on ...
Eli Lilly and Company (LLY) announced on Tuesday that the pharmaceuticals company expects Q4 2024 revenue to be ~$13.5B.
Ricks said at the JPMorgan Healthcare Conference that the government needs to "fix" the Inflation Reduction Act (IRA) before ...
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even faster acceleration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback